{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T18:29:17Z","timestamp":1780338557406,"version":"3.54.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2012,3,19]],"date-time":"2012-03-19T00:00:00Z","timestamp":1332115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2012,3,19]],"date-time":"2012-03-19T00:00:00Z","timestamp":1332115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2012,9]]},"DOI":"10.1038\/leu.2012.71","type":"journal-article","created":{"date-parts":[[2012,3,19]],"date-time":"2012-03-19T07:38:09Z","timestamp":1332142689000},"page":"2114-2123","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Constitutive activation of p38 MAPK in tumor cells contributes to osteolytic bone lesions in multiple myeloma"],"prefix":"10.1038","volume":"26","author":[{"given":"J","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Qian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Matthews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M W","family":"Starbuck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N M","family":"Navone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R Z","family":"Orlowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L W","family":"Kwak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2012,3,19]]},"reference":[{"key":"BFleu201271_CR1","first-page":"983","volume":"19","author":"GD Roodman","year":"2005","unstructured":"Roodman GD . Myeloma bone disease: pathogenesis and treatment. Oncology 2005; 19: 983\u2013984, 986.","journal-title":"Oncology"},{"key":"BFleu201271_CR2","doi-asserted-by":"publisher","first-page":"2483","DOI":"10.1056\/NEJMoa030847","volume":"349","author":"E Tian","year":"2003","unstructured":"Tian E, Zhan F, Walker R, Rasmussen E, Ma Y, Barlogie B et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003; 349: 2483\u20132494.","journal-title":"N Engl J Med"},{"key":"BFleu201271_CR3","doi-asserted-by":"publisher","first-page":"3992","DOI":"10.1182\/blood-2006-05-026112","volume":"108","author":"N Giuliani","year":"2006","unstructured":"Giuliani N, Rizzoli V, Roodman GD . Multiple myeloma bone disease: pathophysiology of osteoblast inhibition. Blood 2006; 108: 3992\u20133996.","journal-title":"Blood"},{"key":"BFleu201271_CR4","doi-asserted-by":"publisher","first-page":"4071","DOI":"10.1182\/blood-2006-04-016980","volume":"108","author":"S Wang","year":"2006","unstructured":"Wang S, Hong S, Yang J, Qian J, Zhang X, Shpall E et al. Optimizing immunotherapy in multiple myeloma: restoring the function of patients\u2019 monocyte-derived dendritic cells by inhibiting p38 or activating MEK\/ERK MAPK and neutralizing interleukin-6 in progenitor cells. Blood 2006; 108: 4071\u20134077.","journal-title":"Blood"},{"key":"BFleu201271_CR5","doi-asserted-by":"publisher","first-page":"2432","DOI":"10.1182\/blood-2005-06-2486","volume":"107","author":"S Wang","year":"2006","unstructured":"Wang S, Yang J, Qian J, Wezeman M, Kwak LW, Yi Q . Tumor evasion of the immune system: inhibiting p38 MAPK signaling restores the function of dendritic cells in multiple myeloma. Blood 2006; 107: 2432\u20132439.","journal-title":"Blood"},{"key":"BFleu201271_CR6","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.exphem.2005.03.001","volume":"33","author":"J Xie","year":"2005","unstructured":"Xie J, Qian J, Yang J, Wang S, Freeman ME, Yi Q . Critical roles of Raf\/MEK\/ERK and PI3K\/AKT signaling and inactivation of p38 MAP kinase in the differentiation and survival of monocyte-derived immature dendritic cells. Exp Hematol 2005; 33: 564\u2013572.","journal-title":"Exp Hematol"},{"key":"BFleu201271_CR7","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1097\/PAP.0b013e31802ef4f2","volume":"14","author":"S Wei","year":"2007","unstructured":"Wei S, Siegal GP . p38 MAPK as a potential therapeutic target for inflammatory osteolysis. Adv Anat Pathol 2007; 14: 42\u201345.","journal-title":"Adv Anat Pathol"},{"key":"BFleu201271_CR8","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1124\/jpet.105.100362","volume":"317","author":"G Mbalaviele","year":"2006","unstructured":"Mbalaviele G, Anderson G, Jones A, De Ciechi P, Settle S, Mnich S et al. Inhibition of p38 mitogen-activated protein kinase prevents inflammatory bone destruction. J Pharmacol Exp Ther 2006; 317: 1044\u20131053.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFleu201271_CR9","doi-asserted-by":"publisher","first-page":"5938","DOI":"10.4049\/jimmunol.0901026","volume":"183","author":"C Bohm","year":"2009","unstructured":"Bohm C, Hayer S, Kilian A, Zaiss MM, Finger S, Hess A et al. The alpha-isoform of p38 MAPK specifically regulates arthritic bone loss. J Immunol 2009; 183: 5938\u20135947.","journal-title":"J Immunol"},{"key":"BFleu201271_CR10","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1172\/JCI200523394","volume":"115","author":"S Wei","year":"2005","unstructured":"Wei S, Kitaura H, Zhou P, Ross FP, Teitelbaum SL . IL-1 mediates TNF-induced osteoclastogenesis. J Clin Invest 2005; 115: 282\u2013290.","journal-title":"J Clin Invest"},{"key":"BFleu201271_CR11","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1182\/blood-2002-06-1874","volume":"101","author":"T Hideshima","year":"2003","unstructured":"Hideshima T, Akiyama M, Hayashi T, Richardson P, Schlossman R, Chauhan D et al. Targeting p38 MAPK inhibits multiple myeloma cell growth in the bone marrow milieu. Blood 2003; 101: 703\u2013705.","journal-title":"Blood"},{"key":"BFleu201271_CR12","doi-asserted-by":"publisher","first-page":"8766","DOI":"10.1038\/sj.onc.1208118","volume":"23","author":"T Hideshima","year":"2004","unstructured":"Hideshima T, Podar K, Chauhan D, Ishitsuka K, Mitsiades C, Tai YT et al. p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells. Oncogene 2004; 23: 8766\u20138776.","journal-title":"Oncogene"},{"key":"BFleu201271_CR13","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1080\/10428190802322919","volume":"49","author":"T Navas","year":"2008","unstructured":"Navas T, Zhou L, Estes M, Haghnazari E, Nguyen AN, Mo Y et al. Inhibition of p38alpha MAPK disrupts the pathological loop of proinflammatory factor production in the myelodysplastic syndrome bone marrow microenvironment. Leuk Lymphoma 2008; 49: 1963\u20131975.","journal-title":"Leuk Lymphoma"},{"key":"BFleu201271_CR14","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/j.yexcr.2006.02.026","volume":"312","author":"AN Nguyen","year":"2006","unstructured":"Nguyen AN, Stebbins EG, Henson M, O\u2019Young G, Choi SJ, Quon D et al. Normalizing the bone marrow microenvironment with p38 inhibitor reduces multiple myeloma cell proliferation and adhesion and suppresses osteoclast formation. Exp Cell Res 2006; 312: 1909\u20131923.","journal-title":"Exp Cell Res"},{"key":"BFleu201271_CR15","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1111\/j.1365-2141.2007.06895.x","volume":"140","author":"J Wen","year":"2008","unstructured":"Wen J, Cheng HY, Feng Y, Rice L, Liu S, Mo A et al. P38 MAPK inhibition enhancing ATO-induced cytotoxicity against multiple myeloma cells. Br J Haematol 2008; 140: 169\u2013180.","journal-title":"Br J Haematol"},{"issue":"1","key":"BFleu201271_CR16","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.leukres.2009.05.024","volume":"34","author":"Jianguo Wen","year":"2010","unstructured":"Wen J, Feng Y, Huang W, Chen H, Liao B, Rice L et al. Enhanced antimyeloma cytotoxicity by the combination of arsenic trioxide and bortezomib is further potentiated by p38 MAPK inhibition. Leuk Res 34: 85\u201392.","journal-title":"Leukemia Research"},{"key":"BFleu201271_CR17","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/S0006-291X(03)00695-8","volume":"305","author":"ZH Lee","year":"2003","unstructured":"Lee ZH, Kim HH . Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts. Biochem Biophys Res Commun 2003; 305: 211\u2013214.","journal-title":"Biochem Biophys Res Commun"},{"key":"BFleu201271_CR18","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1002\/art.21626","volume":"54","author":"J Zwerina","year":"2006","unstructured":"Zwerina J, Hayer S, Redlich K, Bobacz K, Kollias G, Smolen JS et al. Activation of p38 MAPK is a key step in tumor necrosis factor-mediated inflammatory bone destruction. Arthritis Rheum 2006; 54: 463\u2013472.","journal-title":"Arthritis Rheum"},{"key":"BFleu201271_CR19","doi-asserted-by":"publisher","first-page":"4894","DOI":"10.1182\/blood-2008-08-173948","volume":"113","author":"Y Hiruma","year":"2009","unstructured":"Hiruma Y, Honjo T, Jelinek DF, Windle JJ, Shin J, Roodman GD et al. Increased signaling through p62 in the marrow microenvironment increases myeloma cell growth and osteoclast formation. Blood 2009; 113: 4894\u20134902.","journal-title":"Blood"},{"issue":"2","key":"BFleu201271_CR20","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1359\/jbmr.090806","volume":"25","author":"Nobuhiro Kamiya","year":"2009","unstructured":"Kamiya N, Kobayashi T, Mochida Y, Yu PB, Yamauchi M, Kronenberg HM et al. Wnt inhibitors Dkk1 and Sost are downstream targets of BMP signaling through the type IA receptor (BMPRIA) in osteoblasts. J Bone Miner Res 25: 200\u2013210.","journal-title":"Journal of Bone and Mineral Research"},{"key":"BFleu201271_CR21","doi-asserted-by":"publisher","first-page":"4572","DOI":"10.1158\/0008-5472.CAN-06-4361","volume":"67","author":"K Vanderkerken","year":"2007","unstructured":"Vanderkerken K, Medicherla S, Coulton L, De Raeve H, Willems A, Lawson M et al. Inhibition of p38alpha mitogen-activated protein kinase prevents the development of osteolytic bone disease, reduces tumor burden, and increases survival in murine models of multiple myeloma. Cancer Res 2007; 67: 4572\u20134577.","journal-title":"Cancer Res"},{"key":"BFleu201271_CR22","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1182\/blood.V92.8.2908","volume":"92","author":"S Yaccoby","year":"1998","unstructured":"Yaccoby S, Barlogie B, Epstein J . Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. Blood 1998; 92: 2908\u20132913.","journal-title":"Blood"},{"key":"BFleu201271_CR23","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1182\/blood-2006-09-047712","volume":"109","author":"S Yaccoby","year":"2007","unstructured":"Yaccoby S, Ling W, Zhan F, Walker R, Barlogie B, Shaughnessy JD. . Antibody-based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo. Blood 2007; 109: 2106\u20132111.","journal-title":"Blood"},{"key":"BFleu201271_CR24","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1158\/1078-0432.CCR-08-1823","volume":"15","author":"J Yang","year":"2009","unstructured":"Yang J, Cao Y, Hong S, Li H, Qian J, Kwak LW et al. Human-like mouse models for testing the efficacy and safety of anti-beta2-microglobulin monoclonal antibodies to treat myeloma. Clin Cancer Res 2009; 15: 951\u2013959.","journal-title":"Clin Cancer Res"},{"key":"BFleu201271_CR25","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.ccr.2006.08.025","volume":"10","author":"J Yang","year":"2006","unstructured":"Yang J, Qian J, Wezeman M, Wang S, Lin P, Wang M et al. Targeting beta2-microglobulin for induction of tumor apoptosis in human hematological malignancies. Cancer Cell 2006; 10: 295\u2013307.","journal-title":"Cancer Cell"},{"key":"BFleu201271_CR26","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.ccr.2007.08.008","volume":"12","author":"J Yang","year":"2007","unstructured":"Yang J, Wezeman M, Zhang X, Lin P, Wang M, Qian J et al. Human C-reactive protein binds activating Fcgamma receptors and protects myeloma tumor cells from apoptosis. Cancer Cell 2007; 12: 252\u2013265.","journal-title":"Cancer Cell"},{"key":"BFleu201271_CR27","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1038\/leu.2008.336","volume":"23","author":"GD Roodman","year":"2009","unstructured":"Roodman GD . Pathogenesis of myeloma bone disease. Leukemia 2009; 23: 435\u2013441.","journal-title":"Leukemia"},{"key":"BFleu201271_CR28","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1084\/jem.20022033","volume":"197","author":"A Awasthi","year":"2003","unstructured":"Awasthi A, Mathur R, Khan A, Joshi BN, Jain N, Sawant S et al. CD40 signaling is impaired in L. major-infected macrophages and is rescued by a p38MAPK activator establishing a host-protective memory T cell response. J Exp Med 2003; 197: 1037\u20131043.","journal-title":"J Exp Med"},{"key":"BFleu201271_CR29","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1038\/sj.bmt.1705802","volume":"40","author":"GD Roodman","year":"2007","unstructured":"Roodman GD . Treatment strategies for bone disease. Bone Marrow Transplant 2007; 40: 1139\u20131146.","journal-title":"Bone Marrow Transplant"},{"key":"BFleu201271_CR30","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/nm.1945","volume":"15","author":"NB Binder","year":"2009","unstructured":"Binder NB, Niederreiter B, Hoffmann O, Stange R, Pap T, Stulnig TM et al. Estrogen-dependent and C-C chemokine receptor-2-dependent pathways determine osteoclast behavior in osteoporosis. Nat Med 2009; 15: 417\u2013424.","journal-title":"Nat Med"},{"key":"BFleu201271_CR31","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.bone.2007.07.018","volume":"41","author":"D Yan","year":"2007","unstructured":"Yan D, Gurumurthy A, Wright M, Pfeiler TW, Loboa EG, Everett ET . Genetic background influences fluoride\u2019s effects on osteoclastogenesis. Bone 2007; 41: 1036\u20131044.","journal-title":"Bone"},{"key":"BFleu201271_CR32","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.bbrc.2006.10.011","volume":"351","author":"H Huang","year":"2006","unstructured":"Huang H, Chang EJ, Ryu J, Lee ZH, Lee Y, Kim HH . Induction of c-Fos and NFATc1 during RANKL-stimulated osteoclast differentiation is mediated by the p38 signaling pathway. Biochem Biophys Res Commun 2006; 351: 99\u2013105.","journal-title":"Biochem Biophys Res Commun"},{"key":"BFleu201271_CR33","doi-asserted-by":"publisher","first-page":"2025","DOI":"10.1038\/sj.leu.2404806","volume":"21","author":"I von Metzler","year":"2007","unstructured":"von Metzler I, Krebbel H, Hecht M, Manz RA, Fleissner C, Mieth M et al. Bortezomib inhibits human osteoclastogenesis. Leukemia 2007; 21: 2025\u20132034.","journal-title":"Leukemia"},{"key":"BFleu201271_CR34","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1007\/s00296-008-0832-0","volume":"29","author":"HJ Yun","year":"2009","unstructured":"Yun HJ, Lee EG, Lee SI, Chae HJ, Yoo WH . Adrenomedullin inhibits MAPK pathway-dependent rheumatoid synovial fibroblast-mediated osteoclastogenesis by IL-1 and TNF-alpha. Rheumatol Int 2009; 29: 1161\u20131168.","journal-title":"Rheumatol Int"},{"key":"BFleu201271_CR35","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S8756-3282(01)00660-3","volume":"30","author":"A Suzuki","year":"2002","unstructured":"Suzuki A, Guicheux J, Palmer G, Miura Y, Oiso Y, Bonjour JP et al. Evidence for a role of p38 MAP kinase in expression of alkaline phosphatase during osteoblastic cell differentiation. Bone 2002; 30: 91\u201398.","journal-title":"Bone"},{"key":"BFleu201271_CR36","doi-asserted-by":"publisher","first-page":"2457","DOI":"10.1172\/JCI42285","volume":"120","author":"MB Greenblatt","year":"2010","unstructured":"Greenblatt MB, Shim JH, Zou W, Sitara D, Schweitzer M, Hu D et al. The p38 MAPK pathway is essential for skeletogenesis and bone homeostasis in mice. J Clin Invest 2010; 120: 2457\u20132473.","journal-title":"J Clin Invest"},{"key":"BFleu201271_CR37","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S8756-3282(01)00415-X","volume":"28","author":"S Gallea","year":"2001","unstructured":"Gallea S, Lallemand F, Atfi A, Rawadi G, Ramez V, Spinella-Jaegle S et al. Activation of mitogen-activated protein kinase cascades is involved in regulation of bone morphogenetic protein-2-induced osteoblast differentiation in pluripotent C2C12 cells. Bone 2001; 28: 491\u2013498.","journal-title":"Bone"},{"key":"BFleu201271_CR38","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1359\/jbmr.2003.18.11.2060","volume":"18","author":"J Guicheux","year":"2003","unstructured":"Guicheux J, Lemonnier J, Ghayor C, Suzuki A, Palmer G, Caverzasio J . Activation of p38 mitogen-activated protein kinase and c-Jun-NH2-terminal kinase by BMP-2 and their implication in the stimulation of osteoblastic cell differentiation. J Bone Miner Res 2003; 18: 2060\u20132068.","journal-title":"J Bone Miner Res"},{"key":"BFleu201271_CR39","doi-asserted-by":"publisher","first-page":"47257","DOI":"10.1074\/jbc.M208573200","volume":"277","author":"L Wang","year":"2002","unstructured":"Wang L, Ma R, Flavell RA, Choi ME . Requirement of mitogen-activated protein kinase kinase 3 (MKK3) for activation of p38alpha and p38delta MAPK isoforms by TGF-beta 1 in murine mesangial cells. J Biol Chem 2002; 277: 47257\u201347262.","journal-title":"J Biol Chem"},{"key":"BFleu201271_CR40","doi-asserted-by":"publisher","first-page":"7156","DOI":"10.1038\/sj.onc.1205937","volume":"21","author":"KS Lee","year":"2002","unstructured":"Lee KS, Hong SH, Bae SC . Both the Smad and p38 MAPK pathways play a crucial role in Runx2 expression following induction by transforming growth factor-beta and bone morphogenetic protein. Oncogene 2002; 21: 7156\u20137163.","journal-title":"Oncogene"},{"key":"BFleu201271_CR41","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0014-5793(01)03236-7","volume":"510","author":"F Vinals","year":"2002","unstructured":"Vinals F, Lopez-Rovira T, Rosa JL, Ventura F . Inhibition of PI3K\/p70 S6K and p38 MAPK cascades increases osteoblastic differentiation induced by BMP-2. FEBS Lett 2002; 510: 99\u2013104.","journal-title":"FEBS Lett"},{"key":"BFleu201271_CR42","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.beha.2007.08.003","volume":"20","author":"FR Esteve","year":"2007","unstructured":"Esteve FR, Roodman GD . Pathophysiology of myeloma bone disease. Best Pract Res Clin Haematol 2007; 20: 613\u2013624.","journal-title":"Best Pract Res Clin Haematol"},{"key":"BFleu201271_CR43","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/nm0107-25","volume":"13","author":"GD Roodman","year":"2007","unstructured":"Roodman GD . Bone-breaking cancer treatment. Nat Med 2007; 13: 25\u201326.","journal-title":"Nat Med"},{"key":"BFleu201271_CR44","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1111\/j.1365-2141.2008.07044.x","volume":"141","author":"K Ishitsuka","year":"2008","unstructured":"Ishitsuka K, Hideshima T, Neri P, Vallet S, Shiraishi N, Okawa Y et al. p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications. Br J Haematol 2008; 141: 598\u2013606.","journal-title":"Br J Haematol"},{"key":"BFleu201271_CR45","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.leukres.2009.05.024","volume":"34","author":"J Wen","year":"2010","unstructured":"Wen J, Feng Y, Huang W, Chen H, Liao B, Rice L et al. Enhanced antimyeloma cytotoxicity by the combination of arsenic trioxide and bortezomib is further potentiated by p38 MAPK inhibition. Leuk Res 2010; 34: 85\u201392.","journal-title":"Leuk Res"}],"updated-by":[{"DOI":"10.1038\/leu.2014.265","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2015,2,4]],"date-time":"2015-02-04T00:00:00Z","timestamp":1423008000000}}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu201271.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu201271","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu201271.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T15:06:32Z","timestamp":1648739192000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu201271"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3,19]]},"references-count":45,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2012,9]]}},"alternative-id":["BFleu201271"],"URL":"https:\/\/doi.org\/10.1038\/leu.2012.71","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,3,19]]},"assertion":[{"value":"11 November 2011","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 March 2012","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2012","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2012","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}